Stock listing
NYSE American:CLDI Calidi Biotherapeutics, Inc. Stock
Home listing (NYSE American) of Calidi Biotherapeutics, Inc.
Follow Calidi Biotherapeutics, Inc. into a list and get an email when it puts out news.
Share price · AMEX:CLDI
$0.478 USD -0.050 (-9.4%)
Close on Nov 20, 2026
- Day range
- $0.465 – $0.520 USDNov 20, 2026
- Volume
- 47,777 sharesNov 20, 2026
- Market cap
- $1.76M USDAt the close on Nov 20, 2026 · price × 3.68M shares outstanding
- 52-week range
- $0.465 – $24.800 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $106,244 USDMedian day 37,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:CLDI · Home | $0.478 USD | -0.050 (-9.4%) | 47,777 | $0.514 | $0.520 | $0.465 | $0.527 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:CLDI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.478 | -0.050 | -9.4% | $0.514 | $0.520 | $0.465 | 47,777 | |
| $0.527 | -0.032 | -5.8% | $0.556 | $0.580 | $0.516 | 18,425 | |
| $0.560 | -0.043 | -7.1% | $0.593 | $0.593 | $0.549 | 23,784 | |
| $0.602 | -0.020 | -3.2% | $0.650 | $0.650 | $0.600 | 36,516 | |
| $0.622 | -0.033 | -5.1% | $0.656 | $0.656 | $0.622 | 27,090 | |
| $0.655 | -0.020 | -3.0% | $0.678 | $0.701 | $0.640 | 31,383 | |
| $0.675 | -0.009 | -1.3% | $0.694 | $0.728 | $0.670 | 26,662 | |
| $0.684 | -0.049 | -6.7% | $0.733 | $0.734 | $0.683 | 15,275 | |
| $0.733 | +0.033 | +4.7% | $0.701 | $0.765 | $0.673 | 63,100 | |
| $0.700 | +0.021 | +3.1% | $0.690 | $0.710 | $0.679 | 15,720 | |
| $0.679 | -0.051 | -7.0% | $0.711 | $0.711 | $0.630 | 32,273 | |
| $0.730 | -0.019 | -2.5% | $0.760 | $0.792 | $0.650 | 43,280 | |
| $0.749 | +0.091 | +13.8% | $0.630 | $0.760 | $0.630 | 52,484 | |
| $0.658 | -0.030 | -4.4% | $0.698 | $0.710 | $0.649 | 33,023 | |
| $0.688 | +0.016 | +2.4% | $0.667 | $0.688 | $0.650 | 48,393 | |
| $0.672 | -0.030 | -4.3% | $0.650 | $0.706 | $0.650 | 18,203 | |
| $0.702 | +0.042 | +6.3% | $0.700 | $0.719 | $0.664 | 27,526 | |
| $0.660 | +0.020 | +3.1% | $0.669 | $0.700 | $0.623 | 31,284 | |
| $0.640 | -0.005 | -0.8% | $0.650 | $0.650 | $0.630 | 41,419 | |
| $0.645 | -0.005 | -0.8% | $0.650 | $0.660 | $0.629 | 37,600 | |
| $0.650 | -0.118 | -15.4% | $0.770 | $0.770 | $0.620 | 201,100 | |
| $0.768 | -0.002 | -0.3% | $0.759 | $0.790 | $0.731 | 63,700 | |
| $0.770 | -0.013 | -1.7% | $0.750 | $0.779 | $0.750 | 26,900 | |
| $0.783 | -0.054 | -6.5% | $0.801 | $0.831 | $0.751 | 54,800 | |
| $0.837 | -0.033 | -3.8% | $0.890 | $0.890 | $0.790 | 35,100 | |
| $0.870 | -0.004 | -0.5% | $0.870 | $0.890 | $0.857 | 23,800 | |
| $0.874 | -0.026 | -2.9% | $0.900 | $0.920 | $0.820 | 52,800 | |
| $0.900 | -0.050 | -5.3% | $0.933 | $0.933 | $0.870 | 63,800 | |
| $0.950 | -0.080 | -7.8% | $0.998 | $0.998 | $0.937 | 52,600 | |
| $1.030 | -0.010 | -1.0% | $1.040 | $1.050 | $1.030 | 18,000 | |
| $1.040 | +0.030 | +3.0% | $1.020 | $1.041 | $1.000 | 18,200 | |
| $1.010 | -0.010 | -1.0% | $1.020 | $1.030 | $0.986 | 51,500 | |
| $1.020 | -0.030 | -2.9% | $1.060 | $1.070 | $1.000 | 71,700 | |
| $1.050 | -0.030 | -2.8% | $1.080 | $1.120 | $1.000 | 22,000 | |
| $1.080 | 0.000 | 0.0% | $1.090 | $1.090 | $1.050 | 38,600 | |
| $1.080 | +0.010 | +0.9% | $1.065 | $1.080 | $1.050 | 14,900 | |
| $1.070 | -0.010 | -0.9% | $1.080 | $1.095 | $1.050 | 48,900 | |
| $1.080 | +0.010 | +0.9% | $1.075 | $1.080 | $1.030 | 43,200 | |
| $1.070 | -0.060 | -5.3% | $1.100 | $1.130 | $1.050 | 154,500 | |
| $1.130 | -0.070 | -5.8% | $1.200 | $1.290 | $1.130 | 128,600 | |
| $1.200 | +0.110 | +10.1% | $1.150 | $1.250 | $1.100 | 587,800 | |
| $1.090 | -0.020 | -1.8% | $1.100 | $1.150 | $1.050 | 2,882,800 | |
| $1.110 | -0.002 | -0.2% | $1.111 | $1.150 | $1.110 | 37,100 | |
| $1.112 | +0.012 | +1.1% | $1.110 | $1.163 | $1.100 | 33,400 | |
| $1.100 | -0.170 | -13.4% | $1.280 | $1.280 | $1.100 | 30,600 | |
| $1.270 | +0.100 | +8.5% | $1.150 | $1.290 | $1.050 | 189,000 | |
| $1.170 | 0.000 | 0.0% | $1.220 | $1.230 | $1.160 | 32,400 | |
| $1.170 | -0.050 | -4.1% | $1.210 | $1.220 | $1.170 | 33,900 | |
| $1.220 | -0.020 | -1.6% | $1.270 | $1.270 | $1.210 | 17,500 | |
| $1.240 | -0.070 | -5.3% | $1.240 | $1.280 | $1.220 | 70,600 | |
| $1.310 | -0.050 | -3.7% | $1.310 | $1.340 | $1.300 | 32,400 | |
| $1.360 | +0.010 | +0.7% | $1.330 | $1.370 | $1.301 | 45,300 | |
| $1.350 | -0.035 | -2.5% | $1.380 | $1.400 | $1.250 | 30,000 | |
| $1.385 | +0.035 | +2.6% | $1.380 | $1.400 | $1.350 | 19,000 | |
| $1.350 | +0.010 | +0.7% | $1.330 | $1.380 | $1.320 | 23,600 | |
| $1.340 | +0.010 | +0.8% | $1.332 | $1.410 | $1.330 | 30,100 | |
| $1.330 | -0.010 | -0.7% | $1.330 | $1.360 | $1.280 | 48,500 | |
| $1.340 | +0.020 | +1.5% | $1.320 | $1.380 | $1.310 | 35,800 | |
| $1.320 | +0.020 | +1.5% | $1.320 | $1.370 | $1.280 | 51,800 | |
| $1.300 | -0.050 | -3.7% | $1.330 | $1.420 | $1.260 | 129,400 | |
| $1.350 | +0.040 | +3.1% | $1.310 | $1.370 | $1.310 | 38,800 | |
| $1.310 | -0.070 | -5.1% | $1.350 | $1.405 | $1.310 | 48,200 | |
| $1.380 | +0.040 | +3.0% | $1.340 | $1.380 | $1.260 | 62,200 | |
| $1.340 | 0.000 | 0.0% | $1.350 | $1.410 | $1.310 | 58,100 | |
| $1.340 | -0.040 | -2.9% | $1.350 | $1.390 | $1.270 | 79,600 |
Splits
3 splits since 2024 · AMEX:CLDI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-16 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NYSE American:CLDI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · April 2026
Investor Presentation (April 2026)
Investor deck · 13 slides
Latest news
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 13, 2026
Closed $0.602 (-3.2%) on Nov 16, 2026
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Oct 27, 2026
Closed $0.66 (+3.1%) on Oct 27, 2026
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Oct 19, 2026
Closed $0.783 (-6.5%) on Oct 19, 2026
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Sep 17, 2026
Closed $1.27 (+8.5%) on Sep 17, 2026
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 13, 2026
Closed $1.59 (+3.2%) on Aug 14, 2026
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Jul 22, 2026
Closed $1.70 (+6.0%) on Jul 22, 2026
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Jul 20, 2026
Closed $1.60 (-13.8%) on Jul 21, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Jun 24, 2026
Closed $2.51 (+0.6%) on Jun 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Jun 23, 2026
Closed $2.50 (-2.5%) on Jun 23, 2026
Calidi Biotherapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 56 in all · newest Nov 13, 2026 · oldest 2024
- Decks
- 20 decks · latest April 2026
Where Calidi Biotherapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:CLDI · Home listing · This page | NYSE American | United States | USD |
| BOATS:CLDI | BOATS | United States | USD |
Cash and shares
Sep 30, 2025 · Calidi Biotherapeutics — Investor Presentation (October 2025)
- Shares outstanding
- 7,056,312
- Fully diluted
- 12,339,462
Valuation
Price/book 1.1× against a median of 0.3×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.19M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.86
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Calidi Biotherapeutics, Inc. · AMEX:CLDI | US$1.76M | −US$2.19M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.86 |
| CASI Pharmaceuticals, Inc. · OTC:CASIF | US$2.06M | US$38.79M | n/a | 1.9× | n/a | n/a | −218.6% | n/a | -0.07 |
| Vectus Biosystems Limited · ASX:VBS | US$2.02M | US$51,054 | 1.9× | n/a | n/a | 1.3× | n/a | 0.2× | n/a |
| Decoy Therapeutics Inc. · NASDAQ:DCOY | US$1.98M | −US$6.19M | n/a | −11.6× | n/a | 0.4× | n/a | 0.0× | 1.28 |
| Genprex, Inc. · NASDAQ:GNPX | US$1.94M | −US$13.41M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.08 |
| Propanc Biopharma, Inc. · NASDAQ:PPCB | US$1.84M | US$1.62M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.39 |
| Argent Biopharma Ltd · ASX:RGT | US$1.80M | US$8.06M | n/a | 75.4× | n/a | n/a | n/a | n/a | n/a |
| Kala Bio, Inc. · NASDAQ:KALA | US$1.74M | −US$5.49M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 2.76 |
| SOHM, Inc. · OTC:SHMN | US$1.74M | US$4.99M | n/a | 5.5× | n/a | 0.5× | −28.1% | 0.9× | -0.10 |
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Median of the others | US$1.82M | US$689,402 | 1.9× | 3.7× | 0.3× | −123.3% | 0.0× | 1.34 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 120.00 USD · Analysts' mean
- EPS, year to Dec 2025
- -7.44 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Eric Poma | Chief Executive Officer and Director |
| Andrew Jackson | Chief Financial Officer |
| Antonio F. Santidrian | Chief Scientific Officer and Head of Technical Operations |
| Guy Travis Clifton | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| James A. Schoeneck | Chairman of the Board |
| Alan Stewart | Board Member |
| Corsee Sanders | Board Member |
| Eric Poma | Chief Executive Officer and Director |
| George E. Peoples | Board Member |
| Scott Leftwich | Vice-Chairman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −8.1% |
| Q2 2026 | Aug 13, 2026 | −2.5% |
| Q3 2025 | Nov 13, 2025 · After close | −1.3% |
| Q2 2025 | Aug 8, 2025 · After close | +0.6% |
| Q1 2025 | May 14, 2025 · After close | +3.8% |
| Q4 2024 | Mar 31, 2025 | −14.3% |
| Q3 2024 | Nov 12, 2024 · After close | +60.2% |
| Q2 2024 | Aug 13, 2024 · After close | −3.0% |
| Q1 2024 | May 14, 2024 · After close | +3.5% |
| Q4 2023 | Mar 15, 2024 · After close | −5.8% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 14, 2023 · After close | +4.5% |
| Q2 2023 | Aug 30, 2023 | +14.5% |
| Q4 2022 | Mar 31, 2023 | +0.2% |
| Q3 2022 | Nov 14, 2022 | 0.0% |
| Q2 2022 | Aug 10, 2022 | 0.0% |
| Q1 2022 | May 11, 2022 | −0.1% |
| Q4 2021 | Mar 31, 2022 | +0.4% |
| Q3 2021 | Nov 12, 2021 | +0.5% |
| Quarter to Jun 30, 2021 | Sep 13, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 13 slides | April 2026 |
| Investor Presentation (February 2026) | Investor deck | 23 slides | February 2026 |
| Investor Presentation (October 2025) | Investor deck | 22 slides | Oct 24, 2025 |
| Investor Presentation (October 2025) | Investor deck | 22 slides | Oct 22, 2025 |
| Investor Presentation (August 2025) | Investor deck | 16 slides | August 2025 |
| Shareholder Meeting (July 2025) | Shareholder meeting | 14 slides | July 2025 |
| Investor Presentation (March 2025) | Investor deck | 27 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 31 slides | Jan 10, 2025 |
| Investor Presentation (October 2024) | Investor deck | 28 slides | Oct 18, 2024 |
| Corporate Update (September 2024) | Corporate update | 27 slides | Sep 12, 2024 |
All 20 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2024) | Investor deck | 23 slides | Aug 22, 2024 |
| Investor Presentation (April 2024) | Investor deck | 34 slides | Apr 15, 2024 |
| Investor Presentation (April 2024) | Investor deck | 32 slides | April 2024 |
| Biocom Global Life Science Partnering & Investor Conference 2024 | Conference | 18 slides | Feb 28, 2024 |
| Investor Presentation (January 2024) | Investor deck | 33 slides | January 2024 |
| Investor Presentation (December 2023) | Investor deck | 17 slides | Dec 19, 2023 |
| First Light Acquisition Group — SPAC Merger (August 2023) | SPAC merger | 67 slides | Aug 16, 2023 |
| SPAC Merger (February 2023) | SPAC merger | 25 slides | Feb 10, 2023 |
| SPAC Merger (January 2023) | SPAC merger | 25 slides | Jan 9, 2023 |
| SPAC Merger (February 2022) | SPAC merger | 36 slides | Feb 2, 2022 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock Announced: about US$1.2M · US$1.17 a share Use of proceeds: Working capital and general corporate purposes | Sep 17, 2026 |
| Public offering of units of common stock or pre-funded warrants with common warrants Announced: Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes | Mar 5, 2026 |
| Public offering of common stock units and pre-funded warrant units Closed: US$6.9M raised · US$2 a unit · Warrants at US$2 for 60 months · Ladenburg Thalmann & Co. Inc. +1 Dealers: Ladenburg Thalmann & Co. Inc. (lead), Laidlaw & Company (U.K.) Ltd. Insiders: Management and board members participated | Aug 21, 2025 |
| Warrant exercise of warrant inducement offering Closed: US$4.6M raised · US$0.7 a share · ½ warrant at US$0.7 for 66 months · Ladenburg Thalmann & Co, Inc. Dealers: Ladenburg Thalmann & Co, Inc. (lead) Use of proceeds: Advance clinical and pre-clinical programs, continuing operating expenses and working capital | Aug 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as First Light Acquisition Group, Inc., a blank check company (SPAC). Priced at US$10.00 a unit on Sep 9, 2021.
- Price
- US$10.00 a unit
- Units offered
- 20,000,000 units
- Offering size
- US$200 million
- Underwriters' option
- Up to 3,000,000 more units
- Underwriter
- Guggenheim Securities
- Units delivered
- On or about Sep 14, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 17, 2021 |
| Filed publicly | Aug 24, 2021 |
| Amended once | Sep 7, 2021 |
| Shares registered with an exchange | Sep 9, 2021 |
| Declared effective by the SEC | Sep 9, 2021 |
| Final prospectus, with the price | Sep 13, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 13, 2021 |
| EFFECT · Notice that a registration is effective | Sep 9, 2021 |
| CERT · Exchange's certificate of listing | Sep 9, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 9, 2021 |
| CORRESP · Letter to the SEC | Sep 7, 2021 |
| CORRESP · Letter to the SEC | Sep 7, 2021 |
| S-1/A · Registration statement, amended | Sep 7, 2021 |
| CORRESP · Letter to the SEC | Sep 3, 2021 |
| UPLOAD · Letter from the SEC | Aug 30, 2021 |
| S-1 · Registration statement | Aug 24, 2021 |
All 12 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Jul 19, 2021 |
| DRS · Draft registration statement | May 17, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 13, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 45.0K | 449.0K | 0 |
| Cost of revenue | 1.65M | 1.53M | 1.26M | 274.0K | 94.0K | 0 |
| Gross profit | -1.65M | -1.53M | -1.26M | -229.0K | 355.0K | 0 |
| Research and development | 9.74M | 8.88M | 13.0M | 7.26M | 4.67M | 3.18M |
| Selling, general and administrative | 10.5M | 12.9M | 16.0M | 15.9M | 6.16M | 3.59M |
| Operating income | -20.2M | -21.8M | -29.0M | -23.1M | -10.5M | -6.77M |
| Depreciation and amortization | 1.65M | 1.53M | 392.0K | 260.0K | 153.0K | 117.0K |
| EBITDA | -18.6M | -20.2M | -28.6M | -22.9M | -10.3M | -6.66M |
| Interest expense | 100.0K | 700.0K | 1.10M | 200.0K | 614.0K | 163.0K |
| Income before tax | -20.0M | -22.2M | -29.2M | -25.4M | 3.40M | -7.93M |
| Income tax | 15.0K | 14.0K | 16.0K | 11.0K | 11.0K | 4.00K |
| Net income | -19.9M | -22.1M | -29.2M | -25.4M | -10.9M | -7.94M |
| Earnings per share, basic | -5.95 | -35.70 | -17.33 | 2.99 | -733.07 | -42.61 |
| Earnings per share, diluted | -5.95 | -35.70 | -17.33 | 2.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 5.60M | 9.60M | 1.95M | 372.0K | 2.14M | 420.0K |
| Receivables | 1.36M | 870 | ||||
| Current assets | 6.26M | 10.2M | 4.30M | 786.0K | 2.74M | 513.0K |
| Property, plant and equipment | 781.0K | 869.0K | 1.27M | 1.27M | 585.0K | 723.0K |
| Total assets | 8.86M | 14.2M | 10.0M | 2.60M | 3.39M | 1.85M |
| Accounts payable | 595.0K | 2.07M | 2.88M | 51.1K | 624.0K | 822.0K |
| Current liabilities | 3.94M | 9.50M | 10.2M | 43.0M | 26.0M | 8.89M |
| Long-term debt | 600.0K | 600.0K | 2.06M | 6.37M | ||
| Total debt | 600.0K | 600.0K | 2.06M | 5.42M | 5.18M | 11.7M |
| Total liabilities | 5.10M | 12.2M | 18.3M | 43.4M | 26.0M | 24.3M |
| Shareholders' equity | 3.76M | 1.53M | -8.23M | -50.4M | -22.6M | -22.5M |
| Shares outstanding | 451.1K | 1.73M | 3.55M | 8.58M | 14.9K | 186.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -21.3M | -19.7M | -27.0M | -13.2M | -7.77M | -4.83M |
| Capital spending | -120.0K | -16.0K | -585.0K | -428.0K | -206.0K | -351.0K |
| Free cash flow | -21.4M | -19.7M | -27.6M | -13.6M | -7.98M | -5.18M |
| Cash from investing | -170.0K | -16.0K | -478.0K | -494.0K | -215.0K | -388.0K |
| Cash from financing | 17.5M | 27.4M | 29.0M | 12.1M | 9.81M | 4.70M |
| Dividends paid | -5.67M | -1.67M | ||||
| Share buybacks | 0 | -175.0K | ||||
| Change in cash | -3.99M | 7.64M | 1.58M | -968.8K | 1.82M | -514.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 8-K · Current report | Sep 25, 2026 | Current report | SEC |
| 8-K · Current report | Sep 22, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 17, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| 8-K · Current report | Jul 16, 2026 | Material contract | SEC |
| 3 · Initial statement of ownership | Jun 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 29, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | May 8, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 31, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 8-K · Current report | Mar 11, 2026 | Material contract | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 9, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| S-3MEF | Mar 5, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 5, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 28, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 8-K · Current report | Oct 31, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| 8-K · Current report | Sep 19, 2025 | Material contract | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 29, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 27, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 22, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Aug 21, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 15, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 8-K · Current report | Aug 7, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 28, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 25, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jul 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 22, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 18, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 11, 2025 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Jul 10, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jul 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 10, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jul 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 8, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 3, 2025 | Offer document | SEC |
| DRS · Draft registration statement | Jul 2, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | May 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | May 12, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 23, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| 8-K · Current report | Apr 1, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Feb 10, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| 8-K · Current report | Jan 28, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Jan 15, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jan 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jan 8, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Dec 17, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 12, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Nov 29, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| 8-K · Current report | Nov 15, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 15, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 14, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 25-NSE | Oct 28, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 24, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 24, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Oct 23, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 18, 2024 | Current report | SEC |
| 8-K · Current report | Oct 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 11, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Oct 11, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 8, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Oct 7, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 7, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 1, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Oct 1, 2024 | Offer document | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 8-K · Current report | Sep 23, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Sep 12, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 11, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 22, 2024 | Current report | SEC |
| 8-K · Current report | Aug 20, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Aug 19, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2024 | Material contract | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2024 | Material contract | SEC |
| 8-K · Current report | Jul 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2024 | Meeting outcome | SEC |
| D | Jun 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 4, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 4, 2024 | Material contract | SEC |
| 8-K · Current report | May 31, 2024 | Material contract | SEC |
| 8-K · Current report | May 17, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | May 16, 2024 | Offer document | SEC |
| 8-K · Current report | May 16, 2024 | Management or board change | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | May 9, 2024 | Meeting notice | SEC |
| SCHEDULE 13D · Big-stake notice | May 1, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 19, 2024 | Current report | SEC |
| 8-K · Current report | Apr 19, 2024 | Material contract | SEC |
| 8-K · Current report | Apr 18, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Apr 17, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 15, 2024 | Other filings | SEC |
This page holds 200 of 408 filings. Open Filings
Cap table
Built by 6ix from Calidi Biotherapeutics, Inc.’s releases · as of Sep 17, 2026
- Common shares
- 3,676,474
- Fully diluted
- 3,676,474
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,676,474 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.00 · expire about Aug 2030 |
| Warrants · US$0.70 · expire about Jan 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,676,474 |
| Jul 20, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alfonso G. Zulueta Other companies: CTS Corporation (Director · Since at least Apr 16, 2018); Amarin Corporation plc (Director · May 16, 2022 – Jun 27, 2022 · Past); Syneos Health Inc (Director · Jan 15, 2022 – Sep 28, 2023 · Past); Eli Lilly and Company (SVP & President, Lilly Int'l · Jan 1, 2014 – Feb 8, 2021 · Past) | Director · Dec 21, 2023 – Dec 21, 2023 · Past |
| Corazon D Sanders Other companies: BeOne Medicines Ltd. Class A (Director · Since at least May 22, 2026); Legend Biotech Corp. (Director · Since at least Mar 18, 2026); Ultragenyx Pharmaceutical Inc. (Director · Since at least Jun 29, 2021); Molecular Templates Inc (Director · Dec 19, 2019 – Sep 27, 2024 · Past) | Director · Since at least Jun 17, 2026 |
| James A. Schoeneck Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Jul 22, 2025); Kyntra Bio, Inc. (Chairperson of the Board · Since at least Nov 13, 2014); AnaptysBio, Inc. (Director · Jan 25, 2017 – Feb 2, 2018 · Past); Depomed Inc (President and CEO, Director · Dec 10, 2007 – Feb 8, 2017 · Past) | Chairman of the Board · Since at least Sep 12, 2023 |
| George Ng Other companies: TuHURA Biosciences, Inc. (Director · Since at least Oct 18, 2024); Processa Pharmaceuticals, Inc. (Co-Founder and President · Since at least Aug 8, 2023); Sorrento Therapeutics, Inc. (See Remarks · Mar 27, 2015 – Feb 28, 2018 · Past) | Director · Sep 12, 2023 – Sep 12, 2023 · Past |
| Michael J Alber Other companies: Applied Energetics, Inc. (Director · Apr 1, 2024 – Apr 4, 2024 · Past); The KeyW Holding Corporation (CFO/EVP · Jun 13, 2016 – Jun 11, 2019 · Past); Engility Holdings Inc (Senior Vice President and CFO · Jul 2, 2012 – Mar 26, 2014 · Past) | Chief Financial Officer · Sep 9, 2021 – Sep 9, 2021 · Past |
| Andrew Jackson Other companies: Ernexa Therapeutics Inc. (Chief Financial Officer · May 31, 2022 – Jun 3, 2022 · Past); Eiger Biopharmaceuticals Inc (See Remarks · Mar 11, 2015 – Mar 11, 2015 · Past) | Chief Financial Officer · Since at least Oct 30, 2023 |
| Michael C Ruettgers Other companies: Gigamon Inc (Director · Jun 11, 2013 – Dec 27, 2017 · Past); Raytheon Company (Director · May 28, 2009 – May 26, 2016 · Past) | Director · Sep 9, 2021 – Sep 9, 2021 · Past |
| Tony T Kalajian Other companies: Beyond Meat, Inc. (Chief Accounting Officer · Since at least Jan 12, 2026); Insight Molecular Diagnostics Inc. (Sr.VP/Chief Accounting Officer · Aug 9, 2019 – Aug 3, 2020 · Past) | Chief Acctg Officer, Int. CFO · Sep 12, 2023 – Sep 12, 2023 · Past |
| William John Weber Other companies: The KeyW Holding Corporation (President/CEO, Director · Oct 1, 2015 – Jun 11, 2019 · Past); Gtsi Corp (SVP, Professional Services · Apr 23, 2009 – Aug 5, 2009 · Past) | Chief Executive Officer, Director · Sep 9, 2021 – Sep 9, 2021 · Past |
| Alan Stewart Other companies: SoundThinking, Inc. (Chief Financial Officer · Since at least Jun 6, 2017) | Board Member · Since at least Oct 10, 2023 |
All 28 people
| Person | Seat |
|---|---|
| Eric Poma Other companies: Molecular Templates Inc (See remarks, Director · Oct 9, 2017 – Jan 23, 2024 · Past) | Chief Executive Officer · Since at least Apr 22, 2025 |
| Jeanne Tisinger Other companies: C5 Acquisition Corp (Director · Jan 6, 2022 – Jan 6, 2022 · Past) | Director · Sep 9, 2021 – Sep 9, 2021 · Past |
| Thomas A Vecchiolla Other companies: Gencor Industries, Inc. (Director · Sep 30, 2021 – Sep 30, 2021 · Past) | Director · Sep 9, 2021 – Dec 21, 2023 · Past |
| Allan Camaisa | Director · Since at least Sep 12, 2023 |
| Amish Patel | VP of Technical Operations · Sep 12, 2023 – Sep 12, 2023 · Past |
| Antonio F. Santidrian | Chief Scientific Officer and Head of Technical Operations · Since at least May 26, 2026 |
| Boris Radoslavov Minev | Interim Chief Medical Officer · Sep 12, 2023 – Jun 17, 2024 · Past |
| Corsee Sanders | Board Member · Since Jun 17, 2026 |
| David LaPre | Director · Jan 1, 2024 – Jan 1, 2024 · Past |
| David Sans | Chief of Corporate Development · Sep 12, 2023 – Sep 12, 2023 · Past |
| George E. Peoples | Board Member · Since at least Jul 1, 2024 |
| Guy Travis Clifton | Chief Medical Officer · Since at least Jul 29, 2025 |
| Heehyoung Lee | Director · Sep 12, 2023 – Oct 10, 2023 · Past |
| Santidrian Antonio Fernandez | Chief Scientific Officer · Since at least Sep 12, 2023 |
| Scott Leftwich | Vice-Chairman of the Board · Since at least Sep 12, 2023 |
| Stephen Thesing | Chief Business Officer · Sep 12, 2023 – Sep 12, 2023 · Past |
| Wendy Pizarro Campbell | Chief Admin. and Legal Officer · Sep 12, 2023 – Jun 17, 2024 · Past |
| William Fallon | Director · Sep 9, 2021 – Sep 9, 2021 · Past |
Log in to ask 6ix AI your own questions about Calidi Biotherapeutics, Inc.